Literature DB >> 28838210

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G Curigliano1, H J Burstein2, E P Winer2, M Gnant3, P Dubsky3,4, S Loibl5, M Colleoni1, M M Regan6, M Piccart-Gebhart7, H-J Senn8, B Thürlimann9, F André10, J Baselga11, J Bergh12, H Bonnefoi13, S Y Brucker14, F Cardoso15, L Carey16, E Ciruelos17, J Cuzick18, C Denkert19, A Di Leo20, B Ejlertsen21, P Francis22, V Galimberti1, J Garber2, B Gulluoglu23, P Goodwin24, N Harbeck25, D F Hayes26, C-S Huang27, J Huober28, K Hussein29, J Jassem30, Z Jiang31, P Karlsson32, M Morrow11, R Orecchia1, K C Osborne33, O Pagani34, A H Partridge2, K Pritchard35, J Ro36, E J T Rutgers37, F Sedlmayer38, V Semiglazov39, Z Shao40, I Smith41, M Toi42, A Tutt43, G Viale44,45, T Watanabe46, T J Whelan47, B Xu48.   

Abstract

The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  St Gallen Consensus; early breast cancer; radiation therapy; surgery; systemic adjuvant therapies

Mesh:

Substances:

Year:  2017        PMID: 28838210      PMCID: PMC6246241          DOI: 10.1093/annonc/mdx308

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  72 in total

1.  Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Authors:  M Gnant; I Sestak; M Filipits; M Dowsett; M Balic; E Lopez-Knowles; R Greil; P Dubsky; H Stoeger; M Rudas; R Jakesz; S Ferree; J W Cowens; T Nielsen; C Schaper; C Fesl; J Cuzick
Journal:  Ann Oncol       Date:  2015-05-01       Impact factor: 32.976

2.  Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement.

Authors:  Candace Correa; Eleanor E Harris; Maria Cristina Leonardi; Benjamin D Smith; Alphonse G Taghian; Alastair M Thompson; Julia White; Jay R Harris
Journal:  Pract Radiat Oncol       Date:  2016-09-17

3.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

4.  Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

Authors:  Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

5.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

Review 6.  Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review.

Authors:  Lucy De La Cruz; Alison M Moody; Erryn E Tappy; Stephanie A Blankenship; Eric M Hecht
Journal:  Ann Surg Oncol       Date:  2015-08-05       Impact factor: 5.344

7.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

8.  Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy.

Authors:  Stefano Santoro; Andrea Loreti; Francesco Cavaliere; Leopoldo Costarelli; Massimo La Pinta; Elena Manna; Maria Mauri; Paola Scavina; Elena Santini; Ugo De Paula; Vito Toto; Lucio Fortunato
Journal:  Breast       Date:  2015-09-03       Impact factor: 4.380

9.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

10.  Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Authors:  Dennis C Sgroi; Ivana Sestak; Jack Cuzick; Yi Zhang; Catherine A Schnabel; Brock Schroeder; Mark G Erlander; Anita Dunbier; Kally Sidhu; Elena Lopez-Knowles; Paul E Goss; Mitch Dowsett
Journal:  Lancet Oncol       Date:  2013-09-12       Impact factor: 41.316

View more
  284 in total

1.  Axillary web syndrome among Chilean women with breast cancer: incidence and possible predisposing factors.

Authors:  Karol Ramírez-Parada; Diana Garay-Acevedo; Williams Mella-Abarca; Militza Petric-Guajardo; César Sánchez-Rojel; Margaret L McNeely; Ivana Leao-Ribeiro; Rodrigo Fernández-Verdejo
Journal:  Support Care Cancer       Date:  2019-11-25       Impact factor: 3.603

2.  Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients.

Authors:  Jiayi Wu; Weiqi Gao; Xiaosong Chen; Chunxiao Fei; Lin Lin; Weiguo Chen; Ou Huang; Siji Zhu; Jianrong He; Yafen Li; Li Zhu; Kunwei Shen
Journal:  Front Med       Date:  2020-12-06       Impact factor: 4.592

3.  Current Biomarkers for Precision Medicine in Breast Cancer.

Authors:  Soo Kyung Ahn; So-Youn Jung
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Re: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.

Authors:  Paolo Giorgi Rossi; Eugenio Paci
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

5.  Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

Authors:  Meredith M Regan; Gini F Fleming; Barbara Walley; Prudence A Francis; Olivia Pagani
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

6.  Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Authors:  R Colomer; I Aranda-López; J Albanell; T García-Caballero; E Ciruelos; M Á López-García; J Cortés; F Rojo; M Martín; J Palacios-Calvo
Journal:  Clin Transl Oncol       Date:  2018-08       Impact factor: 3.405

Review 7.  Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic.

Authors:  Maureen P McEvoy; Jeffrey Landercasper; Himani R Naik; Sheldon Feldman
Journal:  Gland Surg       Date:  2018-12

8.  Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer.

Authors:  Zhen-Yu Wu; Hee-Jeong Kim; Jong-Won Lee; Il-Yong Chung; Ji-Sun Kim; Sae-Byul Lee; Byung-Ho Son; Jin-Sup Eom; Sung-Bae Kim; Gyung-Yub Gong; Hak-Hee Kim; Sei-Hyun Ahn; BeomSeok Ko
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

9.  Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.

Authors:  Siyu Wu; Yujie Wang; Jianwei Li; Na Zhang; Miao Mo; Suzanne Klimberg; Virginia Kaklamani; Alexandre Cochet; Zhiming Shao; Jingyi Cheng; Guangyu Liu
Journal:  Oncologist       Date:  2019-12-11

10.  Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.

Authors:  Shinsuke Sasada; Norio Masumoto; Eri Suzuki; Satoshi Sueoka; Noriko Goda; Keiko Kajitani; Akiko Emi; Takayuki Kadoya; Morihito Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.